`571-272-7822
`
`Paper: 38
`Entered: March 20, 2024
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`____________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`____________
`
`MYLAN PHARMACEUTICALS, INC.,
`Petitioner,
`
`v.
`
`NOVO NORDISK A/S,
`Patent Owner.
`____________
`
`IPR2023-00724
`Patent 10,335,462 B2
`____________
`
`Before JOHN G. NEW, SUSAN L. C. MITCHELL, and
`ROBERT A. POLLOCK, Administrative Patent Judges.
`
`MITCHELL, Administrative Patent Judge.
`
`
`ORDER
`Granting Patent Owner’s Motions for Admission
`Pro Hac Vice of Jenny C. Wu and Philip S. May
`37 C.F.R. § 42.10
`
`
`
`
`
`IPR2023-00724
`Patent 10,335,462 B2
`
`
`On March 12, 2024, we conditionally granted Patent Owner’s motions
`requesting admission pro hac vice of Jenny C. Wu and Philip S. May.
`Paper 36; see Papers 34 and 35 (collectively, “Motions”). Although Patent
`Owner has demonstrated good cause for the admissions pro hac vice of
`Ms. Wu and Mr. May to serve as back-up counsel, we conditionally granted
`the Motions because
`Patent Owner has not filed a Power of Attorney including
`Ms. Wu or Mr. May in accordance with 37 C.F.R. § 42.10(b).
`Nor has Patent Owner filed Mandatory Notices identifying
`Ms. Wu or Mr. May as back-up counsel in accordance with
`37 C.F.R. § 42.8(b)(3).
`Paper 36, 3.
`
`Upon further review of Patent Owner’s Power of Attorney filing, we
`recognize that Ms. Wu and Mr. May have been designated as representatives
`of Novo Nordisk A/S in the catch-all provision providing authorization for
`“any attorneys from Groombridge, Wu, Baughman & Stone LLP admitted
`pro hac vice in this matter.” See Paper 3, 1. Therefore, Patent Owner’s
`filing of its Second Supplemental Mandatory Notice naming Ms. Wu and
`Mr. May as back-up counsel on March 13, 2024, rendered effective the
`admissions pro hac vice for Ms. Wu and Mr. May. See Paper 37, 1–2.
`In consideration of the foregoing, it is hereby
`ORDERED that Patent Owner’s Motions for admission pro hac vice
`of Jenny C. Wu and Philip S. May are granted;
`FURTHER ORDERED that Patent Owner is to continue to have a
`registered practitioner represent it as lead counsel for this proceeding;
`FURTHER ORDERED that Ms. Wu and Mr. May are authorized to
`represent Patent Owner as back-up counsel only in this proceeding;
`
`
`
`2
`
`
`
`IPR2023-00724
`Patent 10,335,462 B2
`
`
`FURTHER ORDERED that Ms. Wu and Mr. May be familiar with
`the Patent Trial and Appeal Board Consolidated Trial Practice Guide1
`(84 Fed. Reg. 64,280 (Nov. 21, 2019)), and comply with the Board’s Rules
`of Practice for Trials, as set forth in Part 42 of Title 37, Code of Federal
`Regulations; and
`FURTHER ORDERED that Ms. Wu and Mr. May are subject to the
`Office’s disciplinary jurisdiction under 37 C.F.R. § 11.19(a), and the
`USPTO Rules of Professional Conduct set forth in 37 C.F.R. §§ 11.101–
`11.901.
`
`
`
`
`
`
`
`1 Available at https://www.uspto.gov/TrialPracticeGuideConsolidated.
`3
`
`
`
`
`
`IPR2023-00724
`Patent 10,335,462 B2
`
`FOR PETITIONER:
`
`Brandon M. White
`Emily J. Greb
`Courtney Prochnow
`Christopher D. Jones
`Jonathan I. Tietz
`Matthew A. Lembo
`PERKINS COIE LLP
`white-ptab@perkinscoie.com
`greb-ptab@perkinscoie.com
`prochnow-ptab@perkinscoie.com
`jones-ptab@perkinscoie.com
`tietz-ptab@perkinscoie.com
`lembo-ptab@perkinscoie.com
`Semaglutide-Ozempic@perkinscoie.com
`
`FOR PATENT OWNER:
`
`J. Steven Baughman
`Megan Raymond
`GROOMBRIDGE, WU, BAUGHMAN & STONE LLP
`steve.baughman@groombridgewu.com
`megan.raymond@groombridgewu.com
`
`
`
`
`4
`
`